Setmelanotide
Sources
registry, as of 2026-08-06Stale
https://clinicaltrials.gov/study/NCT05093634
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 296. Conditions Obesity; Genetic Obesity. The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-
ClinicalTrials.gov NCT05093634 protocol and results modules
registry, as of 2025-05-31Stale
https://clinicaltrials.gov/study/NCT03651765
Long Term Extension Trial of Setmelanotide. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 205. Conditions Obesity Associated With Defects in Leptin-melanocortin Pathway. This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (M deaths Setmelanotide 0 nausea Setmelanotide 28 vomiting Setmelanotide 21 diarrhoea Setmelanotide 17
ClinicalTrials.gov NCT03651765 protocol and results modules
registry, as of 2026-08-10Stale
https://clinicaltrials.gov/study/NCT05774756
A Trial of Setmelanotide in Acquired Hypothalamic Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 143. Conditions Hypothalamic Obesity. The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO wi Pivotal Cohort: Percentage of Participants With a ≥10% Reduction From Baseline in Body Weight Setmelanotide 55.6 Pivotal Cohort: Percentage of Participants With a ≥10% Reduction From Baseline in Body Weight Placebo 0.05 deaths Setmelanotide 2 nausea Setmelanotide 49 vomiting Setmelanotide 36 diarrhoea Setmelanotide 19 deaths Placebo 0 nausea Placebo 17 vomiting Placebo 14 diarrhoea Placebo 14
ClinicalTrials.gov NCT05774756 protocol and results modules
registry, as of 2023-12-01Stale
https://clinicaltrials.gov/study/NCT03746522
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 52. Conditions Bardet Biedl Syndrome (BBS); Alström Syndrome (AS). This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS). The study's p Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort Pivotal Cohort 32.3 Mean Percent Change From Baseline in Body Weight (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort Pivotal Cohort -5.21 percen
ClinicalTrials.gov NCT03746522 protocol and results modules
registry, as of 2026-02-12Stale
https://clinicaltrials.gov/study/NCT06760546
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756). Overall status RECRUITING. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 39. Conditions Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pitu. This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how w
ClinicalTrials.gov NCT06760546 protocol and results modules
registry, as of 2026-07-15Stale
https://clinicaltrials.gov/study/NCT06596135
Open-Label Extension Study of Setmelanotide. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 28. Conditions Obesity Associated With Defects in Leptin-melanocortin Pathway. This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromi
ClinicalTrials.gov NCT06596135 protocol and results modules
registry, as of 2024-11-26Stale
https://clinicaltrials.gov/study/NCT05194124
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 19. Conditions Bardet-Biedl Syndrome; POMC Deficiency. A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway. deaths Run-in Period: Setmelanotide 2 mg QD 0 diarrhoea Run-in Period: Setmelanotide 2 mg QD 0 nausea Run-in Period: Setmelanotide 2 mg QD 0 vomiting Run-in Period: Setmelanotide 2 mg QD 0 deaths Run-in Period: Setmelanotide 2.5 mg QD 0 diarrhoea Run-in Period: Setmelanotide 2.5 mg QD 0 nausea Run-in Period: Setmelanotide 2.5 mg QD 0 vomiting Run-in Period: Setmelanotide 2.5 mg QD 0 deaths Run-in Period: Setmelanotide 3 mg QD 0 diarrhoea Run-in Period: Setmelanotide 3 mg QD
ClinicalTrials.gov NCT05194124 protocol and results modules
registry, as of 2023-05-23Stale
https://clinicaltrials.gov/study/NCT03287960
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 15. Conditions Leptin Receptor Deficiency Obesity. To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the end of 1 year of treatment. Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) Setmelanotide (Entire Study) 45.5 Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort) Setmelanotide (Entire Study) 53.3 Mean Percent Change From Baseline in Body Weight Setmelanotide (Entire Study) -12.34 Percent change Baseline and Week 52 deaths Setmelanotide 1 na
ClinicalTrials.gov NCT03287960 protocol and results modules
registry, as of 2023-09-21Stale
https://clinicaltrials.gov/study/NCT02896192
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 15. Conditions Pro-opiomelanocortin (POMC) Deficiency Obesity. To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity due to rare biallelic Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) Setmelanotide (Entire Study) 80.0 Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort) Setmelanotide (Entire Study) 85.7 Mean Percent Change From Baseline in Body Weight at Week 52 Setmelanotide (Entire Study) -25
ClinicalTrials.gov NCT02896192 protocol and results modules
registry, as of 2024-11-27Stale
https://clinicaltrials.gov/study/NCT04966741
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 12. Conditions Bardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity. This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein con deaths Setmelanotide: PPL Group 0 vomiting Setmelanotide: PPL Group 4 diarrhoea Setmelanotide: PPL Group 2 deaths Setmelanotide: BBS Group 0 vomiting Setmelanotide: BBS Group 3 diarrhoea Setmelanotide: BBS Group 0
ClinicalTrials.gov NCT04966741 protocol and results modules
registry, as of 2023-08-18Stale
https://clinicaltrials.gov/study/NCT03013543
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 213. Conditions Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency. The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity. Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment 16p11.2 Cohort -2.19 percent change Baseline, Month 3 Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment AS Cohort -6.38 percent change Baseline, Month 3 Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment BBS Cohort -4.19 percent change Baseline, Month 3 Percent Change From Bas
ClinicalTrials.gov NCT03013543 protocol and results modules
registry, as of 2025-07-02Stale
https://clinicaltrials.gov/study/NCT04963231
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 164. Conditions Genetic Obesity. The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway. Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype Overall: Change at Week 16 Stage 1: Setmelanotide (Open-Label) -3.94 percent change Baseline, Week 16 Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype Gene: NRP2, Change at Week 16 Stage 1: Setmelanotide (Open-Label) -1.37 percent change Baseline, Week 16 Percent Chan
ClinicalTrials.gov NCT04963231 protocol and results modules
registry, as of 2023-08-07Stale
https://clinicaltrials.gov/study/NCT02041195
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 99. Conditions Overweight and Obesity. The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. deaths Stage A: Placebo 0.75 mg BID 0 nausea Stage A: Placebo 0.75 mg BID 0 vomiting Stage A: Placebo 0.75 mg BID 0 diarrhoea Stage A: Placebo 0.75 mg BID 0 deaths Stage A: Placebo 1.5 mg QD 0 nausea Stage A: Placebo 1.5 mg QD 1 vomiting Stage A: Placebo 1.5 mg QD 0 diarrhoea Stage A: Placebo 1.5 mg QD 0 deaths Stage B: Placebo 1.5 mg QD 0 nausea Stage B: Placebo 1.5 mg QD 1 vomiting Stage
ClinicalTrials.gov NCT02041195 protocol and results modules
registry, as of 2023-08-14Stale
https://clinicaltrials.gov/study/NCT01749137
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 74. Conditions Overweight. The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants. The study is designed to evaluate the efficacy and toler Percent Change From Baseline in Body Weight Setmelanotide -2.0 Percent change Baseline and Day 90 Percent Change From Baseline in Body Weight Placebo -0.3 Percent change Baseline and Day 90 Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight Setmelanotide 9.1 Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight Placebo 5.6 Percent Change From Baseline in Body Weight in Severely
ClinicalTrials.gov NCT01749137 protocol and results modules
registry, as of 2023-07-27Stale
https://clinicaltrials.gov/study/NCT02311673
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 40. Conditions Prader-Willi Syndrome. The purpose of this study was to evaluate the effects of a once daily subcutaneous injectable formulation of setmelanotide in obese participants with Prader-Willi syndrome on tolerability, weight loss, and hyperphagia-related behavior. The study drug (setmelanotide and placebo) w Percent Change From Baseline in Body Weight - Period 4 Setmelanotide 1.5 mg (Open-Label Extension) -0.0 percent change Baseline (Day 56) and Day 70 Percent Change From Baseline in Body Weight - Period 4 Setmelanotide 2.5 mg (Open-Label Extension) 0.0 percent change Baseline (Day 56) and Day 70 deaths Setmelanotide 0.5 mg (Double-blind Randomized Treatment) 0 nau
ClinicalTrials.gov NCT02311673 protocol and results modules